Co-Diagnostics, Inc.
CODXCo-Diagnostics, Inc. in brief
Co-Diagnostics, Inc. is a listed company in the Diagnostics and Research industry, based in Salt Lake City, Utah, USA. Its market value was $4 M on 30 October 2026, which makes it the 27,081st largest listed company in the world and the 4,427th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $47 M. Dwight H. Egan is its chief executive. Its largest product and service lines by sales in 2025 were Grant (33%). By market, the largest shares of its 2025 sales came from USA (93%). Its shares trade under the symbol CODX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc is a molecular diagnostics technology and innovation in disease detection and life sciences research through its enhanced detection of genetic material company. The headquarters is in USA.
Co-Diagnostics, Inc. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 13 July 2017; shares registered for exchange trading on 11 July 2017.
- 2021
- 💰Record revenue of $98 millionFY2021, the highest of the 8 years on record.
Events of Co-Diagnostics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,571 (Jan 2022) · #4,456 (Dec 2022) · #4,850 (Jul 2023) · #4,146 (Jan 2024) · #4,048 (Aug 2026) · #4,194 (Oct 2026) · #4,429 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 4.9×
- Price / book
- 0.2×
- Free cash flow yield
- -710.5%
- Net margin (TTM)
- -5520.9%
- Operating margin
- -8091.9%
- Return on equity
- -230.2%
- Liabilities / assets
- 16.6%
- Net debt
- $1M
- Revenue growth
- -84.2%
- R&D / revenue
- 3087.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | -84.2% | $-50M | $-47M | -7564.5% |
| Dec 2024 | $4M | -42.4% | $-40M | $-38M | -960.2% |
| Dec 2023 | $7M | -80.1% | $-43M | $-35M | -518.8% |
| Dec 2022 | $34M | -65.0% | $-27M | $-14M | -41.6% |
| Dec 2021 | $98M | +31.3% | $46M | $37M | 37.5% |
| Dec 2020 | $75M | +35400.0% | $42M | $42M | 57.0% |
| Dec 2019 | $0M | +425.0% | $-6M | $-6M | -2952.4% |
| Dec 2018 | $0M | — | $-6M | $-6M | -15675.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-29M | $1M | $-30M | $-35.25 | — |
| Dec 2024 | $-29M | $1M | $-30M | $-37.22 | — |
| Dec 2023 | $-22M | $1M | $-23M | $-1.20 | — |
| Dec 2022 | $7M | $1M | $5M | $-0.45 | — |
| Dec 2021 | $41M | $1M | $40M | $1.23 | — |
| Dec 2020 | $28M | $1M | $27M | $1.52 | — |
| Dec 2019 | $-6M | $0M | $-6M | $-0.37 | — |
| Dec 2018 | $-4M | $0M | $-4M | $-0.50 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $0M (+86.7% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 26, 2026DEF 14AProxy statement
- Oct 15, 20268-KCurrent reportShareholder vote
- Oct 15, 20268-K/ACurrent report (amended)Material agreement · New financial obligation · Unregistered share sale
- Oct 13, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Oct 5, 20268-KCurrent reportShareholder vote
- Sep 25, 20268-KCurrent reportShareholder vote
- Sep 16, 20268-KCurrent reportRegulation FD disclosure
- Sep 16, 20268-KCurrent reportOther events
- Sep 15, 20268-KCurrent reportOther events
- Sep 4, 20268-KCurrent reportDirectors or officers changed
Official filings of Co-Diagnostics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-50 M
- Net income
- $-47 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $25 M
- Total liabilities
- $4 M
- Total equity
- $21 M
As of December-2025
Top 24 institutional investors in Co-Diagnostics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 58,275 | 0 (0.00%) | 0.55% | $0 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 49,599 | +24,024 (+93.94%) | 0.47% | $0 M | Nov 6, 2026 |
| 3 | Private Advisory Group LLC | 39,387 | 0 (0.00%) | 0.37% | $0 M | Nov 6, 2026 |
| 4 | HRT Financial LP | 30,355 | New | 0.29% | $0 M | Nov 13, 2026 |
| 5 | Citigroup Inc | 25,301 | New | 0.24% | $0 M | Nov 4, 2026 |
| 6 | Jane Street Group, LLC | 24,086 | -65,154 (-73.01%) | 0.23% | $0 M | Nov 12, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 19,776 | 0 (0.00%) | 0.19% | $0 M | Nov 13, 2026 |
| 8 | Susquehanna International Group, LLP | 15,986 | -15,253 (-48.83%) | 0.15% | $0 M | Nov 16, 2026 |
| 9 | State Street Corp | 14,800 | 0 (0.00%) | 0.14% | $0 M | Nov 12, 2026 |
| 10 | Tower Research Capital LLC (TRC) | 7,684 | New | 0.07% | $0 M | Nov 16, 2026 |
| 11 | Jpmorgan Chase & Co | 1,993 | +1,990 (+66333.33%) | 0.02% | $0 M | Nov 12, 2026 |
| 12 | UBS Group AG | 1,477 | -14,614 (-90.82%) | 0.01% | $0 M | Nov 10, 2026 |
| 13 | Morgan Stanley | 1,452 | -1,425 (-49.53%) | 0.01% | $0 M | Nov 13, 2026 |
| 14 | SBI Securities Co., Ltd. | 140 | +59 (+72.84%) | 0.00% | $0 M | Oct 22, 2026 |
| 15 | Smartleaf Asset Management LLC | 133 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 16 | Berthel, Fisher & Company Financial Services, Inc. | 100 | New | 0.00% | $0 M | Nov 13, 2026 |
| 17 | Wells Fargo & Company/mn | 81 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 18 | Osaic Holdings, Inc. | 10 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 19 | BFC Planning, Inc. | 8 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 20 | NewEdge Advisors, LLC | 6 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 21 | Pinnacle Financial Group, Inc. | 6 | — | 0.00% | $0 M | Nov 16, 2026 |
| 22 | FMR LLC | 4 | -3 (-42.86%) | 0.00% | $0 M | Nov 10, 2026 |
| 23 | Harbour Investments, Inc. | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 24 | Northwestern Mutual Wealth Management Co | 1 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Co-Diagnostics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 58,275 | $0 M | 0.55% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 39 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Co-Diagnostics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Eugene DurenardDirector | Grant or award | +1,695 | — | — | 10,668 | Form 4 |
| filed | Brian Lee BrownChief Financial Officer | Grant or award | +3,750 | — | — | 23,729 | Form 4 |
| filed | Edward L. MurphyDirector | Grant or award | +1,695 | — | — | 11,084 | Form 4 |
| filed | Dwight H. EganChief Executive Officer, Director | Grant or award | +4,584 | — | — | 29,526 | Form 4 |
| filed | Richard David AbbottPresident | Grant or award | +1,890 | — | — | 4,097 | Form 4 |
| filed | James B. NelsonDirector | Grant or award | +1,695 | — | — | 10,668 | Form 4 |
| filed | Richard S. SerbinDirector | Grant or award | +1,695 | — | — | 10,751 | Form 4 |
| filed | Dwight H. EganChief Executive Officer, Director | Disposal to the company | -1,633 | $5.070 | $8 K | 27,893 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Co-Diagnostics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2023 | Q4 2023 | $0.2M |
| Q3 2023 | Q3 2023 | $0.2M |
| Q2 2023 | Q2 2023 | $0.6M |
| Q1 2023 | Q1 2023 | $0.5M |
| Q4 2022 | Q4 2022 | $1.2M |
| Q3 2022 | Q3 2022 | $10.4M |
Trading halts
- 2026-07-01 18:25 UTC, code LUDP, resumed 18:30 UTC
- 2026-07-01 13:56 UTC, code LUDP, resumed 14:01 UTC
- 2026-07-01 13:40 UTC, code LUDP, resumed 13:50 UTC
- 2026-06-02 13:35 UTC, code LUDP, resumed 13:45 UTC
- 2026-05-27 14:54 UTC, code LUDP, resumed 15:04 UTC
Fails to deliver
- : 32,988 shares at $0.40
- : 3,204 shares at $0.44
- : 207 shares at $0.55
- : 16,865 shares at $0.64
- : 1,506 shares at $0.72
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Co-Diagnostics, Inc. scorecard#
Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.2×Price to book 0.2× against Diagnostics and Research's median of 3.7×.
- ✗Price to sales below its peers' median4.9×Price to sales 4.9× against Diagnostics and Research's median of 4.5×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 3
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-35.25 vs -37.22Diluted EPS -35.25 in fiscal 2025 against -37.22 the year before (report's currency).
- ✗Net income higher than five years earlier-$47 M-$47 M in fiscal 2025 against $42 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$47 MNet income -$47 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-125.9%-125.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.9×Current ratio 3.87 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-10.11Z-score -10.11 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year31.6%Diluted shares up 31.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Co-Diagnostics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.6−84.1%100% | 3.9−42.5%100% | 6.8−80.1%100% | 34−65.0%100% | 98+31.3%100% | 75+34580%100% | 0.2+439%100% | 0.0+421%100% | 0.0—100% | — | |
| Cost of revenue | 0.2−77.7%35.7% | 1.0−76.1%25.5% | 4.2−23.6%61.4% | 5.5r5.5−52.6%16.0% | 12−30.2%11.8% | 17+14657%22.3% | 0.1+1097%52.3% | 0.0+3010%23.5% | 0.0—3.9% | — | |
| Gross profit | 0.4−86.3%64.3% | 2.9+11.0%74.5% | 2.6−90.9%38.6% | 29r29−66.7%84.0% | 86+48.9%88.2% | 58+56424%77.7% | 0.1+236%47.7% | 0.0+315%76.5% | 0.0—96.1% | — | |
| Research and development | 19−8.8%3074% | 21−8.6%536% | 23+31.7%337% | 17+16.5%51.0% | 15+370%15.3% | 3.2+132%4.3% | 1.4+0.8%638% | 1.4+35.7%3410% | 1.0+37.1%13093% | 0.7—— | |
| Selling and marketing | 2.4−46.9%383% | 4.5−34.7%115% | 6.9−6.6%101% | 7.3−45.2%21.5% | 13+187%13.7% | 4.7+339%6.3% | 1.1−8.9%494% | 1.2+173%2921% | 0.4+249%5569% | 0.1—— | |
| General and administrative | 9.1−43.9%1455% | 16+13.1%413% | 14+0.1%210% | 14+23.5%41.7% | 12+39.5%11.8% | 8.3+137%11.1% | 3.5−2.1%1627% | 3.6+15.3%8947% | 3.1+288%40404% | 0.8—— | |
| Operating expenses | 51+17.6%8123% | 43−5.2%1098% | 45−18.6%665% | 56+38.4%163% | 40+147%41.1% | 16+171%21.8% | 6.0−2.5%2789% | 6.1+34.5%15405% | 4.6+171%59664% | 1.7—— | |
| Operating income | −50—−8059% | −40—−1024% | −43—−627% | −27r−27−159%−78.8% | 46+10.5%47.1% | 42—55.9% | −5.9—−2742% | −6.1—−15329% | −4.6—−59568% | −1.7—— | |
| Interest expense and finance costs | — | — | — | — | — | — | 0.1r0.1+49.9%49.5% | 0.1−77.1%178% | 0.3+28.9%4049% | 0.2—— | |
| Other non-operating income (expense) | 1.7−33.9%266% | 2.5−45.6%63.8% | 4.6−43.5%67.5% | 8.1r8.1—23.8% | −0.4−149%−0.4% | 0.9—1.2% | −0.3—−140% | −0.2—−386% | −2.4—−31260% | — | |
| Income before tax | −49—−7793% | −38—−960% | −38—−559% | −19−141%−55.1% | 46+7.2%46.6% | 43—57.1% | −6.2—−2882% | −6.3—−15714% | −7.0—−90828% | −1.9—— | |
| Income tax | −1.6−2917%−260% | 0.1—1.5% | −2.8—−40.8% | −4.6−151%−13.5% | 9.0+9816%9.2% | 0.1—0.1% | — | — | — | — | |
| Net income attributable to shareholders | −47—−7534% | −38—−961% | −35—−519% | −14−139%−41.6% | 37−13.7%37.5% | 42—57.0% | −6.2—−2882% | −6.3—−15714% | −7.0—−90828% | −1.9—— | |
| Earnings per share, basic | -35.25—— | -37.22r-1.24—— | -1.20—— | -0.45−135%— | 1.27−20.1%— | 1.59—— | -0.37r-0.36—— | -0.50—— | -0.63—— | — | |
| Earnings per share, diluted | -35.25—— | -37.22r-1.24—— | -1.20—— | -0.45−137%— | 1.23−19.1%— | 1.52—— | -0.37r-0.36—— | -0.50—— | -0.63—— | — | |
| Shares, weighted average (basic) | 1.3+31.5%— | 1.0r30−96.6%— | 29−6.8%— | 31+9.0%— | 29+8.1%— | 27+59.5%— | 17—— | — | — | — | |
| Shares, weighted average (diluted) | 1.3+31.5%— | 1.0r30−96.6%— | 29−6.8%— | 31+5.3%— | 30+6.8%— | 28+67.1%— | 17+34.2%— | 12+13.9%— | 11+10.9%— | 9.9—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 12+305%48.0% | 2.9−80.3%4.6% | 15−35.1%15.6% | 23−74.1%18.7% | 89+106%55.4% | 43+4712%60.3% | 0.9−6.0%40.3% | 1.0−73.1%61.2% | 3.5+254%75.8% | 1.0—77.1% | |
| Short-term investments | — | 27−38.6%42.2% | 44−25.1%45.8% | 58+4544%47.4% | 1.3−71.0%0.8% | 4.3—6.1% | — | — | — | — | |
| Receivables | 0.2+43.6%0.8% | 0.1−56.4%0.2% | 0.3−91.2%0.3% | 3.5−83.4%2.8% | 21+71.7%13.0% | 12+9138%17.0% | 0.1+879%5.9% | 0.0—0.9% | — | — | |
| Inventory | 1.0−7.5%4.0% | 1.1−35.6%1.7% | 1.7−68.7%1.7% | 5.3+165%4.3% | 2.0−74.9%1.3% | 8.0+3955%11.2% | 0.2+986%8.9% | 0.0+100%1.2% | 0.0—0.2% | — | |
| Other current assets | 0.6−56.6%2.4% | 1.3−16.2%2.1% | 1.6+110%1.7% | 0.8r0.8−67.4%0.6% | 2.3—1.5% | — | — | — | — | — | |
| Current assets | 14−57.6%55.3% | 32−48.0%50.8% | 62−33.0%65.2% | 93r93−19.4%75.3% | 115+69.8%71.9% | 68r68+4180%95.2% | 1.6+50.6%71.5% | 1.1−76.4%67.7% | 4.5+268%95.5% | 1.2—93.3% | |
| Property, plant and equipment | 2.3−17.7%9.2% | 2.8−9.0%4.3% | 3.0+19.5%3.2% | 2.5+31.4%2.1% | 1.9+104%1.2% | 0.9+382%1.3% | 0.2r0.2+26.1%8.9% | 0.2−5.7%10.1% | 0.2+89.4%3.6% | 0.1—6.7% | |
| Right-of-use (leased) assets | 1.2−42.9%4.9% | 2.1−28.7%3.3% | 3.0+697%3.1% | 0.4—0.3% | — | — | — | — | — | — | |
| Goodwill | — | — | — | — | 15—9.2% | — | — | — | — | — | |
| Other intangible assets | 7.2−72.3%29.2% | 26−1.1%41.1% | 26−1.4%27.7% | 27−1.6%21.7% | 27—17.0% | — | — | — | — | — | |
| Non-current assets | — | — | — | — | — | — | 0.6+25.9%28.5% | 0.5+138%32.3% | 0.2+141%4.5% | 0.1—6.7% | |
| Total assets | 25−61.1%100% | 64r64−33.3%100% | 95−22.6%100% | 123r123−23.1%100% | 160+125%100% | 71+3116%100% | 2.2+42.6%100% | 1.6−66.7%100% | 4.7+260%100% | 1.3—100% | |
| Accounts payable | 1.9−43.0%7.6% | 3.3+122%5.2% | 1.5+55.6%1.6% | 1.0r1.0+56.8%0.8% | 0.6+1.5%0.4% | 0.6+9941%0.8% | 0.0−96.0%0.3% | 0.1+265%9.6% | 0.0+36.4%0.9% | 0.0—2.3% | |
| Customer deposits | — | — | — | — | — | — | 0.3—11.5% | — | 2.2—47.2% | — | |
| Debt due within a year | — | — | — | — | — | — | — | 1.9—123% | — | 2.6—197% | |
| Current liabilities | 3.5−51.6%14.3% | 7.3+27.3%11.5% | 5.7+48.4%6.0% | 3.9r3.9−69.3%3.1% | 13+210%7.9% | 4.1r4.5+1138%5.7% | 0.3−86.1%14.8% | 2.4+274%151% | 0.6r0.6−83.7%13.5% | 3.8—297% | |
| Long-term debt | — | — | — | — | — | — | — | 1.9+587%123% | 0.3—6.0% | — | |
| Lease liabilities (non-current) | 0.6−53.6%2.3% | 1.2−42.5%1.9% | 2.2+4144%2.3% | 0.1—0.0% | — | — | — | — | — | — | |
| Non-current liabilities | 0.6−75.8%2.3% | 2.4−33.4%3.7% | 3.6−24.2%3.7% | 4.7−63.8%3.8% | 13+2613%8.1% | 0.5r0.0+219%0.7% | 0.2−42.3%6.8% | 0.3+41.7%16.7% | 0.2r0.2−58.8%3.9% | 0.4—34.3% | |
| Total liabilities | 4.1−57.5%16.6% | 9.7+4.1%15.2% | 9.3+8.6%9.8% | 8.6r8.6−66.5%7.0% | 26+463%16.0% | 4.5+850%6.4% | 0.5−81.7%21.6% | 2.6+222%168% | 0.8−81.1%17.4% | 4.3—331% | |
| Retained earnings | −80—−325% | −33r−33−828%−52.7% | 4.6−88.5%4.8% | 40r40−26.3%32.4% | 54+209%33.8% | 18—24.6% | −25—−1127% | −19—−1204% | −12—−266% | −5.5—−422% | |
| Shareholders' equity | 21−61.7%83.4% | 54r54−37.0%84.8% | 86r86−25.3%89.8% | 115r115−14.8%93.0% | 134r134+102%84.0% | 67+3739%93.6% | 1.7—78.4% | −1.1−127%−68.2% | 3.9—82.6% | −3.0—−231% | |
| Total liabilities and equity | 25−61.1%100% | 64r64−33.3%100% | 95−22.6%100% | 123r123−23.1%100% | 160+125%100% | 71+3116%100% | 2.2+42.6%100% | 1.6−66.7%100% | 4.7+260%100% | 1.3—100% | |
| Shares outstanding | 2.1+90.1%— | 1.1r33−96.5%— | 31+1.3%— | 31−8.7%— | 34+18.4%— | 29+64.7%— | 17+34.2%— | 13r13+4.9%— | 12+24.6%— | 9.9r9.9—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.1−19.6%178% | 1.4+11.9%35.2% | 1.2−4.1%18.1% | 1.3+282%3.7% | 0.3+142%0.3% | 0.1+110%0.2% | 0.1+29.8%30.7% | 0.1+10.9%127% | 0.0+22.1%597% | 0.0—— | |
| Share-based compensation | 2.2−58.6%361% | 5.4−34.8%139% | 8.3+10.5%122% | 7.5+36.9%22.0% | 5.5+101%5.6% | 2.7+152%3.7% | 1.1−18.3%506% | 1.3−34.5%3338% | 2.0+2824%26546% | 0.1—— | |
| Cash from operating activities | −29—−4681% | −29—−745% | −22−436%−324% | 6.6−84.0%19.2% | 41+45.9%42.0% | 28—37.8% | −5.5—−2570% | −4.1—−10223% | −3.2—−41913% | −1.3—— | |
| Capital expenditure | −0.7—−112% | −0.7—−19.1% | −1.4—−20.0% | −1.4—−4.2% | −0.7—−0.7% | −0.8—−1.0% | −0.1—−52.7% | −0.0—−104% | −0.1—−1688% | −0.0—— | |
| Acquisitions, net of cash acquired | — | — | — | — | −1.2—−1.2% | — | — | — | — | — | |
| Cash from investing activities | 26+53.9%4221% | 17+10.9%436% | 15—226% | −58−1519%−170% | 4.1—4.2% | −5.8—−7.8% | −0.4—−202% | −0.4—−953% | −0.2—−2471% | −0.0—— | |
| Debt issued | — | — | — | — | — | — | — | 2.0—5011% | — | — | |
| Shares issued | — | — | — | 0.2−60.5%0.5% | 0.5−97.7%0.5% | 19+254%26.1% | 5.5+18220%2557% | 0.0−99.6%75.2% | 7.1—92289% | — | |
| Shares bought back | — | — | −1.4—−20.0% | −14—−41.5% | — | — | — | — | — | — | |
| Cash from financing activities | 12+11267%1897% | 0.1—2.7% | −1.4—−20.0% | −14−3216%−41.0% | 0.5−97.7%0.5% | 20+234%26.5% | 5.9+215%2746% | 1.9−68.4%4701% | 5.9+159%77479% | 2.3—— | |
| Change in cash | 8.9—1437% | −12—−306% | −8.1—−118% | −66−244%−192% | 46+8.4%46.6% | 42—56.4% | −0.1—−26.6% | −2.6−202%−6475% | 2.5+163%33095% | 1.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.9+69.1%100% | 0.3+94.6%100% | 0.2+2.0%100% | 0.1+190%100% | 0.3*+76.7%100% | 0.1−77.3%100% | 0.2−93.9%100% | 0.1−89.3%100% | 0.1*−95.8%100% | 0.6—100% | 2.7—100% | 0.5—100% | 3.6*—100% | |
| Cost of revenue | 0.7+104%79.7% | 0.3+1054%107% | 0.0+41.1%27.3% | 0.2+797%133% | 0.1*−44.2%54.0% | 0.0−91.2%18.1% | 0.0−84.9%19.7% | 0.0−90.8%42.9% | 0.3*−91.4%171% | 0.3—46.4% | 0.2—8.0% | 0.2—50.1% | 3.0*—83.5% | |
| Gross profit | 0.2+0.7%20.3% | −0.0−117%−7.2% | 0.1−7.6%72.7% | −0.0−267%−32.8% | 0.1*—46.0% | 0.1−65.4%81.9% | 0.1−94.6%80.3% | 0.0−87.7%57.1% | −0.1*−118%−70.8% | 0.3—53.6% | 2.4—92.0% | 0.2—49.9% | 0.6*—16.5% | |
| Research and development | 19−0.5%2184% | 3.6−20.2%1264% | 4.2−11.4%2499% | 5.9+21.8%4066% | 5.1*+6.1%1932% | 4.5−8.2%3082% | 4.7−16.5%2877% | 4.9−14.3%9686% | 4.8*−22.2%3219% | 4.9—761% | 5.6—211% | 5.7—1214% | 6.2*—174% | |
| Selling and marketing | 2.1−22.4%240% | 0.6+1.9%205% | 0.5−23.5%281% | 0.5−28.8%321% | 0.5*−33.4%207% | 0.6−46.3%391% | 0.6−41.4%374% | 0.7−58.0%1307% | 0.8*−46.0%548% | 1.1—165% | 1.0—39.2% | 1.6—334% | 1.5*—42.7% | |
| General and administrative | 7.7−40.5%902% | 1.9+3.1%662% | 1.5−42.3%903% | 2.5−9.7%1715% | 1.9*−67.9%708% | 1.8−57.6%1249% | 2.6−17.0%1596% | 2.8−5.0%5516% | 5.8*+32.1%3897% | 4.3—669% | 3.1—118% | 2.9—624% | 4.4*—124% | |
| Operating expenses | 48+35.5%5635% | 6.2−12.4%2209% | 6.3−22.8%3805% | 9.2+6.8%6276% | 27*+126%10103% | 7.1−32.6%4906% | 8.2−19.1%5026% | 8.6−18.2%17067% | 12*−4.9%7903% | 11—1650% | 10—381% | 10—2243% | 12*—349% | |
| Operating income | −48—−5614% | −6.3—−2216% | −6.2—−3732% | −9.2—−6309% | −27*—−10057% | −7.0—−4824% | −8.1—−4946% | −8.6—−17010% | −12*—−7974% | −10—−1596% | −7.7—−289% | −10—−2193% | −12*—−333% | |
| Other non-operating income (expense) | 0.3−86.8%33.9% | −0.0—−12.9% | −0.1−119%−38.4% | 0.1−93.3%47.2% | 0.3*−62.8%122% | −0.0−107%−27.2% | 0.3+236%209% | 1.0+6.2%2050% | 0.9*−11.7%581% | 0.6—87.4% | 0.1—3.8% | 1.0—207% | 1.0*—27.6% | |
| Income before tax | −48—−5580% | −6.3—−2229% | −6.3—−3771% | −9.1—−6262% | −26*—−9935% | −7.1—−4852% | −7.7—−4737% | −7.5—−14960% | −11*—−7393% | −9.7—−1509% | −7.6—−285% | −9.3—−1986% | −11*—−305% | |
| Income tax | −0.5—−52.8% | 0.0—0.2% | 0.0+55.5%11.5% | 0.0−95.7%0.4% | −0.5*—−179% | −1.2−5358%−802% | 0.0−40.1%7.6% | 0.0−47.3%23.9% | −0.0*−100%−5.5% | 0.0—3.5% | 0.0—0.8% | 0.0—4.9% | 3.8*—108% | |
| Net income attributable to shareholders | −47—−5528% | −6.3—−2229% | −6.3—−3782% | −9.1—−6262% | −26*—−9755% | −5.9—−4049% | −7.7—−4745% | −7.5—−14984% | −11*—−7387% | −9.7—−1512% | −7.6—−286% | −9.3—−1990% | −15*—−413% | |
| Earnings per share, basic | — | -1.01—— | -1.46—— | -4.06—— | — | -4.66r-0.16—— | -7.00r-0.23—— | -7.05r-0.24—— | — | -0.32—— | -0.25—— | -0.31—— | — | |
| Earnings per share, diluted | — | -1.01—— | -1.46—— | -4.06—— | — | -4.66r-0.16—— | -7.00r-0.23—— | -7.05r-0.24—— | — | -0.32—— | -0.25—— | -0.31—— | — | |
| Shares, weighted average (basic) | 6.3+397%— | 6.3+397%— | 4.3+291%— | 2.3+111%— | — | 1.3r38−95.9%— | 1.1r33−96.3%— | 1.1r32−96.4%— | — | 30—— | 30—— | 30—— | — | |
| Shares, weighted average (diluted) | 6.3+397%— | 6.3+397%— | 4.3+291%— | 2.3+111%— | — | 1.3r38−95.9%— | 1.1r33−96.3%— | 1.1r32−96.4%— | — | 30—— | 30—— | 30—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.7—5.6% | 0.7−93.8%5.6% | 3.6−67.2%22.0% | 8.2+333%38.3% | 12+305%48.0% | 11+6.0%25.6% | 11−19.8%23.9% | 1.9−91.8%3.5% | 2.9−80.3%4.6% | 11—14.9% | 14—17.2% | 23—26.7% | 15—15.6% | |
| Short-term investments | — | — | — | — | — | — | 2.2−92.8%4.8% | 20−27.1%35.5% | 27−38.6%42.2% | 27—37.1% | 31—38.4% | 27—31.0% | 44—45.8% | |
| Receivables | 0.1—0.4% | 0.1−7.3%0.4% | 0.1−75.3%0.3% | 0.1−39.6%0.4% | 0.2+43.6%0.8% | 0.1−68.6%0.1% | 0.2−61.7%0.5% | 0.1−68.6%0.2% | 0.1−56.4%0.2% | 0.2—0.2% | 0.6—0.7% | 0.4—0.5% | 0.3—0.3% | |
| Inventory | 0.7—5.3% | 0.7−38.3%5.3% | 0.8−22.4%5.1% | 0.8−21.9%3.9% | 1.0−7.5%4.0% | 1.1−13.9%2.4% | 1.1−25.9%2.3% | 1.1−30.1%2.0% | 1.1−35.6%1.7% | 1.3—1.7% | 1.5—1.8% | 1.5—1.8% | 1.7—1.7% | |
| Other current assets | 0.5—3.9% | 0.5−8.0%3.9% | 0.6−0.0%3.9% | 0.6−45.0%2.9% | 0.6−56.6%2.4% | 0.5−45.6%1.2% | 0.6−51.0%1.4% | 1.1−35.3%2.1% | 1.3−16.2%2.1% | 1.0—1.4% | 1.3—1.6% | 1.8—2.0% | 1.6—1.7% | |
| Current assets | 1.9—15.2% | 1.9−86.2%15.2% | 5.2−66.1%31.3% | 9.8−59.0%45.5% | 14−57.6%55.3% | 14−65.0%31.4% | 15−68.3%32.9% | 24−55.6%43.2% | 32−48.0%50.8% | 40—55.4% | 48—59.8% | 54—62.0% | 62—65.2% | |
| Property, plant and equipment | 1.8—13.8% | 1.8−28.9%13.8% | 2.0−26.1%11.9% | 2.2−16.8%10.0% | 2.3−17.7%9.2% | 2.5−16.7%5.6% | 2.7−12.5%5.8% | 2.6−18.5%4.7% | 2.8−9.0%4.3% | 3.0—4.1% | 3.1—3.8% | 3.2—3.7% | 3.0—3.2% | |
| Right-of-use (leased) assets | 1.5—12.0% | 1.5+6.4%12.0% | 1.8+6.0%10.7% | 2.0+5.8%9.3% | 1.2−42.9%4.9% | 1.4−38.3%3.2% | 1.7−34.5%3.6% | 1.9−31.4%3.4% | 2.1−28.7%3.3% | 2.3—3.2% | 2.5—3.2% | 2.8—3.2% | 3.0—3.1% | |
| Other intangible assets | 7.2—56.4% | 7.2−72.3%56.4% | 7.2−72.3%43.5% | 7.2−72.3%33.6% | 7.2−72.3%29.2% | 26−0.3%58.3% | 26−0.6%56.2% | 26−0.9%47.3% | 26−1.1%41.1% | 26—36.2% | 26—32.5% | 26—30.4% | 26—27.7% | |
| Total assets | 13—100% | 13−71.4%100% | 17−64.3%100% | 21−61.0%100% | 25−61.1%100% | 45−38.2%100% | 46−42.4%100% | 55−36.4%100% | 64r64−33.3%100% | 72—100% | 81—100% | 87—100% | 95—100% | |
| Accounts payable | 0.9—7.3% | 0.9−35.7%7.3% | 1.1−34.1%6.5% | 2.0−25.6%9.4% | 1.9−43.0%7.6% | 1.5−33.0%3.3% | 1.6−12.3%3.5% | 2.7+33.8%4.9% | 3.3+122%5.2% | 2.2—3.0% | 1.9—2.3% | 2.0—2.3% | 1.5—1.6% | |
| Current liabilities | 2.5—19.6% | 2.5−32.0%19.6% | 2.9−22.8%17.3% | 4.3−20.3%19.9% | 3.5−51.6%14.3% | 3.7−36.3%8.3% | 3.7−30.0%8.0% | 5.4+2.0%9.7% | 7.3+27.3%11.5% | 5.8—8.0% | 5.3—6.6% | 5.3—6.1% | 5.7—6.0% | |
| Lease liabilities (non-current) | 0.9—6.7% | 0.9+17.4%6.7% | 1.0+15.4%6.1% | 1.2+14.0%5.5% | 0.6−53.6%2.3% | 0.7−50.6%1.6% | 0.9−48.4%1.9% | 1.0−46.8%1.9% | 1.2−42.5%1.9% | 1.5—2.0% | 1.7—2.1% | 1.9—2.2% | 2.2—2.3% | |
| Non-current liabilities | 0.9—6.7% | 0.9−29.9%6.7% | 1.0−37.2%6.1% | 1.2−36.7%5.5% | 0.6−75.8%2.3% | 1.2−56.4%2.7% | 1.6−46.1%3.5% | 1.9−39.3%3.4% | 2.4−33.4%3.7% | 2.8—3.9% | 3.0—3.7% | 3.0—3.5% | 3.6—3.7% | |
| Total liabilities | 3.4—26.3% | 3.4−31.5%26.3% | 3.9−27.2%23.4% | 5.5−24.5%25.4% | 4.1−57.5%16.6% | 4.9−42.9%11.0% | 5.3−35.8%11.5% | 7.2−13.1%13.1% | 9.7+4.1%15.2% | 8.6—11.9% | 8.3—10.3% | 8.3—9.6% | 9.3—9.8% | |
| Retained earnings | −102—−798% | −102—−798% | −96—−577% | −90—−416% | −80—−325% | −54—−121% | −48—−104% | −41—−73.6% | −33r−33−828%−52.7% | −22—−30.4% | −12—−15.3% | −4.7—−5.4% | 4.6—4.8% | |
| Shareholders' equity | 9.4—73.7% | 9.4−76.1%73.7% | 13−68.8%76.6% | 16−66.2%74.6% | 21−61.7%83.4% | 39r40−38.2%88.0% | 41r41−43.8%87.6% | 47r48−39.4%86.1% | 54r54−37.0%84.8% | 64—88.1% | 72—89.7% | 78—90.4% | 86r86—89.8% | |
| Total liabilities and equity | 13—100% | 13−71.4%100% | 17−64.3%100% | 21−61.0%100% | 25−61.1%100% | 45−38.2%100% | 46−42.4%100% | 55−36.4%100% | 64r64−33.3%100% | 72—100% | 81—100% | 87—100% | 95—100% | |
| Shares outstanding | 7.3—— | 7.3−84.9%— | 4.9−86.5%— | 3.6−89.3%— | 2.1+90.1%— | 48+50.8%— | 36+13.4%— | 34+7.3%— | 1.1r33−96.5%— | 32—— | 32—— | 31—— | 31—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.9−20.8%110% | 0.2−16.8%78.6% | 0.2−30.7%121% | 0.3−8.9%175% | 0.3*−25.1%101% | 0.3−23.9%184% | 0.3−13.9%179% | 0.3−15.2%558% | 0.4*+14.1%239% | 0.4—54.8% | 0.3—12.7% | 0.3—70.7% | 0.3*—8.8% | |
| Share-based compensation | 1.0−70.1%114% | 0.3*−49.0%90.2% | 0.2*−63.2%129% | 0.2−75.0%150% | 0.3*−77.9%111% | 0.5−52.1%344% | 0.6−61.3%356% | 0.9−44.3%1741% | 1.3*−27.8%883% | 1.0—163% | 1.5—56.4% | 1.6—336% | 1.8*—51.4% | |
| Cash from operating activities | −27—−3130% | −5.7*—−2009% | −7.2*—−4306% | −7.8—−5376% | −6.2*—−2349% | −5.9*—−4061% | −8.3*—−5087% | −8.7—−17394% | −8.2*—−5512% | −7.2*—−1128% | −5.2*—−196% | −8.5—−1815% | −4.8*—−134% | |
| Capital expenditure | −0.3—−35.8% | −0.0*—−5.3% | −0.0*—−11.0% | −0.1—−97.3% | −0.1*—−50.0% | −0.1*—−51.7% | −0.4*—−246% | −0.1—−183% | −0.1*—−48.9% | −0.2*—−27.2% | −0.1*—−3.7% | −0.4—−86.0% | −0.5*—−13.1% | |
| Cash from investing activities | −0.7−102%−76.2% | −0.0*−101%−5.3% | −0.2*−101%−101% | −0.1−102%−97.3% | −0.3*−224%−125% | 2.2*−47.8%1496% | 17*—10479% | 7.4−55.9%14633% | 0.3*−97.2%178% | 4.2*—650% | −4.0*—−152% | 17—3564% | 9.6*—270% | |
| Shares bought back | — | — | — | — | — | — | — | — | — | — | — | — | −0.2*—−4.5% | |
| Cash from financing activities | 17—1957% | 2.8*−31.9%977% | 2.7*+539%1649% | 4.3+1122%2970% | 7.0*—2641% | 4.1*—2792% | 0.4*—263% | 0.4—706% | — | — | — | — | −0.2*—−4.5% | |
| Change in cash | −11−1760%−1249% | −2.9*−993%−1037% | −4.6*−150%−2758% | −3.7—−2503% | 0.4*—167% | 0.3*—226% | 9.2*—5655% | −1.0−113%−2056% | −7.9*−268%−5264% | −3.1*—−477% | −9.2*—−348% | 8.2—1749% | 4.7*—132% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Co-Diagnostics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$0 M67%-45%
- Grant$0 M33%-94%
Countries and regions
- 🇺🇸 USA$1 M93%-84%
- Non-US(total)$0 M6.6%-90%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Co-Diagnostics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dwight Egan | $529 K | $276 K | $391 K | $13 |
| 2024Dwight Egan | $717 K | $421 K | $501 K | $56 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Co-Diagnostics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 1 · Material agreement 8 · Agreement ended 1 · New debt 2 · Unregistered share sale 4 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 6 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K/A | |
| Shareholder vote | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2021 | $47 M | Private placement after listing | $10 to $50 million | 22 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Co-Diagnostics, Inc. compares in Diagnostics and Research
- Market cap$4 M · higher than 2% of 110
- Revenue$1 M · higher than 5% of 123
- Revenue growth-84.2% · higher than 1% of 89
- Price / sales4.9× · lower than 43% of 85
- Price / book0.2× · lowest of 84
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Co-Diagnostics, Inc.🇺🇸 | $4 M | — | — | -84.2% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Co-Diagnostics, Inc.? Verify and update this profile — free
Show Co-Diagnostics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.